Table 3.
Comparison of Baseline Characteristics Between Patients Who Experienced MACE and Those Who Did Not During the Median Follow-Up of 3.5 Years
| MACE (n=5) | No MACE (n=52) | p | |||
|---|---|---|---|---|---|
| Characteristic | |||||
| Age, years–mean (SD) | 75.0 | (9.9) | 63.4 | (9.5) | 0.031 |
| Male gender–n (%) | 5 | (100) | 37 | (71) | 0.162 |
| BMI–mean (SD) | 22.6 | (3.3) | 29.7 | (4.3) | 0.311 |
| STEMI at admission–n (%) | 2 | (40) | 42 | (81) | 0.072 |
| CV risk factors–n (%) | |||||
| Arterial hypertension | 4 | (80) | 32 | (62) | 0.642 |
| Diabetes mellitus | 1 | (20) | 15 | (29) | 1.000 |
| Dyslipidaemia | 2 | (60) | 35 | (67) | 0.332 |
| Smoking | 1 | (20) | 24 | (46) | 0.372 |
| Clinical data | |||||
| eGFR, mL/min–median (IQR) | 57 | (43.50–73 | 90 | (68.50–113) | 0.007 |
| Hb, g/dl–mean (SD) | 12.9 | (1.3) | 13.9 | (1.3) | 0.335 |
| LDL-C–median (IQR) | 136 | (52–188) | 123 | (91–151) | 0.922 |
| NT-proBNP–median (IQR) | 3307 | (1034–3579) | 764 | (305–1893) | 0.109 |
| Plt count, 103/μL–mean (SD) | 212 | (28) | 226 | (69) | 0.129 |
| TnI max, ng/mL–median (IQR) | 52.5 | (23.2–104.8) | 12.1 | (3.1–36.4) | 0.048 |
| LVEF, %–mean (SD) | 40.0 | (7.1) | 49.8 | (8.9) | 0.446 |
| Pharmacotherapy at discharge | |||||
| Aspirin–n (%) | 5 | (100) | 52 | (100) | 1.000 |
| P2Y12 inhibitor–n (%) | 5 | (100) | 52 | (100) | 1.000 |
| Statin–n (%) | 5 | (100) | 51 | (98) | 0.754 |
| β-blocker–n (%) | 5 | (100) | 47 | (90) | 0.468 |
| ACE-inhibitor or ARB–n (%) | 5 | (100) | 50 | (96) | 0.655 |
| Diuretics–n (%) | 2 | (40) | 13 | (25) | 0.467 |
| Aldosterone antagonists–n (%) | 3 | (60) | 10 | (19) | 0.072 |
| Protein pump inhibitor–n (%) | 5 | (100) | 49 | (94) | 0.581 |
| Cardiac rehabilitation–n (%) | 4 | (80) | 40 | (77) | 0.437 |
Note: The statistically significant differences are marked bold.
Abbreviations: SD, standard deviation; BMI, body mass index; STEMI, ST-segment elevation myocardial infarction; eGFR, estimated glomerular filtration rate, calculated with the Cockcroft-Gault equation; IQR, interquartile range; Hb, haemoglobin; LDL-C, low-density lipoprotein-cholesterol; NT-proBNP, N-terminal pro-b-type natriuretic peptide; Plt, platelets; LVEF, left ventricular ejection fraction; ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blockers.